Ipsen's Stock Rebounds Over 2%, Marking One of the Top Gains in SBF 120
The biopharmaceutical company stands out at the week's close, moving against the downtrend of the Parisian market. The rebound comes after several sessions of decline that had brought the stock below its short-term moving averages.
A 2.2% Rebound Bringing the Stock Close to Its 20-Day Moving Average
Ipsen's stock gains 2.2% to €157.80, while the CAC 40 drops by 0.32% and the SBF 120 by 0.35%. The stock is among the top performers in the SBF 120 session.
However, the rebound does not offset the monthly decline: the performance stands at -5.23% over one month and -3.6% over three months. Over one year, the stock still holds a gain of 51%.
Technically, the price is just below its MM20 (€159.50, a gap of -1.07%) and MM50 (€161.50, a gap of -2.29%), while it remains significantly above the MM200 at €137.35 (+14.89%). The RSI at 43 remains neutral, with no signs of exhaustion or strong momentum.
Active Clinical Pipeline and Employee Savings Plan in 36 Countries
The underlying context remains supportive. At the end of May, the company presented at the EASL congress new data confirming the effectiveness of Iqirvo in primary biliary cholangitis, with improvements observed in 67% of patients according to the results published on May 28.
On June 1, the group also launched an employee savings plan in 36 countries, set at €130.96 per share. This fifth operation of its kind since 2016 targets employees with at least three months of seniority.
In its May 2026 publication, the company also noted among its risks the competition from generics and regulatory uncertainty surrounding new treatments. The next technical milestone is the MM20 at €159.50, whose reconquest would condition the exit from the consolidation phase that began in mid-May.
